Kexing Pharmaceutical released its semi-annual report "Innovative R&D + Product Introduction" with remarkable progress

On the evening of August 29, Kexing Pharmaceutical (688136.

On the evening of August 29, Kexing Pharmaceutical (688136.

Under the guidance of the national strategy of the new era of high-quality development, Kexing Pharmaceutical focuses on the vision and goal of becoming a "leader in high-quality biological drugs", based on the field of biological drugs, improves the quality of business decisions, consolidates organizational capacity building, and adjusts in a multi-faceted way to cope with the global economic situation and market changes

According to the data results of the statistics of The Intranet, its core product "Sai ruojin" ranked first in the market share of domestic short-acting injectable human interferon in 2021, with a market share of 30.

Continuous R&D breakthroughs In the field of anti-virus, continuous R&D breakthroughs in the field of anti-virus continue to develop breakthroughs In the field of anti-virus

Since the beginning of this year, the research and development of Kexing Pharmaceutical has continued to make great progress, and the growth of R&D investment has reached a new high! In the first half of the year, the company's R & D investment of 0.

Since the beginning of this year, the research and development of Kexing Pharmaceutical has continued to make great progress, and the growth of R&D investment has reached a new high! In the first half of the year, the company's R & D investment of 0.

Shenzhen Kexing, a wholly-owned subsidiary of Kexing Pharmaceutical, signed the "SHEN26 Project Cooperation Agreement" with Shenzhen Antaiwei Company at the beginning of the year, which aroused strong concern in

Secondly, a number of pipelines independently developed by Kexing Pharmaceutical began to make progress this year, and the company's ren erythropoietin injection 36000IU obtained the "Notice of Approval of Drug Supplement Application" approved and issued by the State Food and Drug Administration, adding "anemia caused by chemotherapy for non-bone marrow malignant tumors" indications, which have been listed for sale; Human erythropoietin 10000IU has completed the supplementary application declaration and clinical center verification; Clinical trial applications for polyethylene glycolated human granulocyte stimulating factor injection have been accepted

New crown small molecule oral drugs SHEN26, human interferon α1b and α2b are antiviral drugs, as the company's core product line, the perfect layout of the series of pipelines and research and development to promote, for the follow-up long-term profitability to bring growth momentum, the company is expected to grow into a leader

Active layout of new industries Follow-up growth momentum sufficient Active layout of new industries Follow-up growth momentum sufficient Active layout of new industries Follow-up growth momentum sufficient Follow-up growth momentum is sufficient

Under the double impact of the domestic and international environment, the pharmaceutical industry is facing unprecedented survival pressure, and enterprises must seek more business breakthroughs

Under the double impact of the domestic and international environment, the pharmaceutical industry is facing unprecedented survival pressure, and enterprises must seek more business breakthroughs

Kexing Pharmaceutical has set its sights on the leading technology in China, genetic engineering vector vaccine, and in March 2022, it invested in the establishment of Shenzhen Kexing Dongbao Biotechnology Co.

According to the statistics and forecasts of QYR (Hengzhou Primus), the global veterinary vaccine market sales reached 8.

Kexing Pharmaceutical's entry into animal vaccine research and development not only leverages the economic animal vaccine market that has exceeded 10 billion, but also covers the pet vaccine market

At the same time, Kexing Pharmaceutical actively carries out industry-university-research cooperation

Thick accumulation and thin development Commercialization ability highlights thick accumulation and thin hair Commercial ability highlights thick accumulation and thin development Commercial ability highlights

At present, kexing pharmaceutical's domestic marketing terminals cover more than 19,000 hospitals, primary medical institutions and pharmacies, including nearly 7,000 hospitals, more than 8,000 third terminals, and more than 4,000 pharmacies; With more than 20 years of overseas commercialization experience in biological drugs, it has passed the market access and sales of nearly 40 countries and regions around the world, such as Brazil, the Philippines, Egypt, etc.

At present, kexing pharmaceutical's domestic marketing terminals cover more than 19,000 hospitals, primary medical institutions and pharmacies, including nearly 7,000 hospitals, more than 8,000 third terminals, and more than 4,000 pharmacies; With more than 20 years of overseas commercialization experience in biological drugs, it has passed the market access and sales of nearly 40 countries and regions around the world, such as Brazil, the Philippines, Egypt, etc.
, and holds more than 60 drug access certificates
from overseas countries and regions.
In the first half of 2022, Kexing Pharmaceutical will open the efficient reform and empowerment of functions and marketing modules, adjust the organizational structure, strengthen organizational construction, improve organizational functions, integrate and build organizational platforms and market platforms, improve organizational synergy performance, and strengthen the core capabilities
of various functional areas of the company 。 At present, kexing pharmaceutical's domestic marketing terminals cover more than 19,000 hospitals, primary medical institutions and pharmacies, including nearly 7,000 hospitals, more than 8,000 third terminals, and more than 4,000 pharmacies; With more than 20 years of overseas commercialization experience in biological drugs, it has passed the market access and sales of nearly 40 countries and regions around the world, such as Brazil, the Philippines, Egypt, etc.
, and holds more than 60 drug access certificates
from overseas countries and regions.
In the first half of 2022, Kexing Pharmaceutical will open the efficient reform and empowerment of functions and marketing modules, adjust the organizational structure, strengthen organizational construction, improve organizational functions, integrate and build organizational platforms and market platforms, improve organizational synergy performance, and strengthen the core capabilities
of various functional areas of the company.

Only by accumulating the internal strength of the marketing organization can there be enough energy to accelerate the pace of
"going out".
In the past two years, a number of advantageous products have been introduced, and on the basis of enriching their own anti-tumor, immunity and other key track product lines, its fundamental purpose is to strengthen Kexing Pharmaceutical, an overseas commercialization platform
that has begun to take shape.
At present, the commercialization of a number of products that the company has introduced is progressing in an orderly manner, and the progress of channel expansion and overseas registration has also been frequently reported
.

Only by accumulating the internal strength of the marketing organization can there be enough energy to accelerate the pace of
"going out".
In the past two years, a number of advantageous products have been introduced, and on the basis of enriching their own anti-tumor, immunity and other key track product lines, its fundamental purpose is to strengthen Kexing Pharmaceutical, an overseas commercialization platform
that has begun to take shape.
At present, the commercialization of a number of products that the company has introduced is progressing in an orderly manner, and the progress of channel expansion and overseas registration has also been frequently reported
.
Only by accumulating the internal strength of the marketing organization can there be enough energy to accelerate the pace of
"going out".
In the past two years, a number of advantageous products have been introduced, and on the basis of enriching their own anti-tumor, immunity and other key track product lines, its fundamental purpose is to strengthen Kexing Pharmaceutical, an overseas commercialization platform
that has begun to take shape.
At present, the commercialization of a number of products that the company has introduced is progressing in an orderly manner, and the progress of channel expansion and overseas registration has also been frequently reported
.

In the first half of the year, Kexing Pharmaceutical and Dongyao Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Suzhou Dongyao") signed the "Exclusive Commercialization License Cooperation Agreement for Bevacizumab Drugs in overseas markets", and Kexing Pharmaceutical obtained the exclusive commercialization license of Suzhou Dongyao Bevacizumab drugs in all countries and regions in the world except China, the European Union (subject to the EU member states in 2021), the United Kingdom, the United States and Japan (hereinafter referred to as the "Cooperation Area"), and has now launched product registration
in 11 countries.

In the first half of the year, Kexing Pharmaceutical and Dongyao Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Suzhou Dongyao") signed the "Exclusive Commercialization License Cooperation Agreement for Bevacizumab Drugs in overseas markets", and Kexing Pharmaceutical obtained the exclusive commercialization license of Suzhou Dongyao Bevacizumab drugs in all countries and regions in the world except China, the European Union (subject to the EU member states in 2021), the United Kingdom, the United States and Japan (hereinafter referred to as the "Cooperation Area"), and has now launched product registration
in 11 countries 。 In the first half of the year, Kexing Pharmaceutical and Dongyao Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Suzhou Dongyao") signed the "Exclusive Commercialization License Cooperation Agreement for Bevacizumab Drugs in overseas markets", and Kexing Pharmaceutical obtained the exclusive commercialization license of Suzhou Dongyao Bevacizumab drugs in all countries and regions in the world except China, the European Union (subject to the EU member states in 2021), the United Kingdom, the United States and Japan (hereinafter referred to as the "Cooperation Area"), and has now launched product registration
in 11 countries.

Following the exclusive commercial license of Infliximab (class stop) in all countries and regions except Chinese mainland, Japan, Europe, and North America, Coxing Pharmaceutical has acquired the exclusive promotion service rights and interests of Chinese mainland market, and has submitted registration documents in 13 countries, and the company will submit registration documents
in 12 countries in the second half of the year.
At the same time, the domestic sales of Infliximab have also been launched, a professional promotion service team has been set up, the company's commercial cooperation in the field of self-exemption has been expanded, and it has achieved network sales in 32 provinces across the country, covering more than 100 hospitals, further enhancing the company's competitiveness and profitability
.

Following the exclusive commercial license of Infliximab (class stop) in all countries and regions except Chinese mainland, Japan, Europe, and North America, Coxing Pharmaceutical has acquired the exclusive promotion service rights and interests of Chinese mainland market, and has submitted registration documents in 13 countries, and the company will submit registration documents
in 12 countries in the second half of the year.
At the same time, the domestic sales of Infliximab have also been launched, a professional promotion service team has been set up, the company's commercial cooperation in the field of self-exemption has been expanded, and it has achieved network sales in 32 provinces across the country, covering more than 100 hospitals, further enhancing the company's competitiveness and profitability
.
Following the exclusive commercial license of Infliximab (class stop) in all countries and regions except Chinese mainland, Japan, Europe, and North America, Coxing Pharmaceutical has acquired the exclusive promotion service rights and interests of Chinese mainland market, and has submitted registration documents in 13 countries, and the company will submit registration documents
in 12 countries in the second half of the year.
At the same time, the domestic sales of Infliximab have also been launched, a professional promotion service team has been set up, the company's commercial cooperation in the field of self-exemption has been expanded, and it has achieved network sales in 32 provinces across the country, covering more than 100 hospitals, further enhancing the company's competitiveness and profitability
.

In addition, the introduction of albumin paclitaxel last year has also entered the review and approval stage of the Drug Evaluation Center of the State Drug Administration (NMPA) and the technical review process of the European Medicines Agency (EMA), and it is understood that the company is making every effort to promote the construction of production lines, quality system certification, customer development and other work
.

In addition, the introduction of albumin paclitaxel last year has also entered the review and approval stage of the Drug Evaluation Center of the State Drug Administration (NMPA) and the technical review process of the European Medicines Agency (EMA), and it is understood that the company is making every effort to promote the construction of production lines, quality system certification, customer development and other work
。 In addition, the introduction of albumin paclitaxel last year has also entered the review and approval stage of the Drug Evaluation Center of the State Drug Administration (NMPA) and the technical review process of the European Medicines Agency (EMA), and it is understood that the company is making every effort to promote the construction of production lines, quality system certification, customer development and other work
.

In the future, Kexing Pharmaceutical will continue to consolidate the management foundation, improve the quality of operation, introduce advanced management methods, enrich the layout of R&D pipelines, accelerate the global commercialization process, and implement lean management to continuously improve organizational performance
.
Under the background of the severe global economic situation, the high-quality management level and steady and solid pre-development progress allow the market to see that Kexing Pharmaceutical is a high-quality enterprise with great growth potential, which adheres to the belief of "sci-tech" all the way, guards global doctors and patients, and strives to become a "leader in high-quality biological drugs"
.

In the future, Kexing Pharmaceutical will continue to consolidate the management foundation, improve the quality of operation, introduce advanced management methods, enrich the layout of R&D pipelines, accelerate the global commercialization process, and implement lean management to continuously improve organizational performance
.
Under the background of the severe global economic situation, the high-quality management level and steady and solid pre-development progress allow the market to see that Kexing Pharmaceutical is a high-quality enterprise with great growth potential, which adheres to the belief of "sci-tech" all the way, guards global doctors and patients, and strives to become a "leader in high-quality biological drugs"
.
In the future, Kexing Pharmaceutical will continue to consolidate the management foundation, improve the quality of operation, introduce advanced management methods, enrich the layout of R&D pipelines, accelerate the global commercialization process, and implement lean management to continuously improve organizational performance
.
Under the background of the severe global economic situation, the high-quality management level and steady and solid pre-development progress allow the market to see that Kexing Pharmaceutical is a high-quality enterprise with great growth potential, which adheres to the belief of "sci-tech" all the way, guards global doctors and patients, and strives to become a "leader in high-quality biological drugs"
.

Miracle of Mind: Stroke Sequela BATA Conditioning!